Trial Profile
Proof-of-concept study of ibrutinib in c-MYC and HER2 amplified gastrooesophageal carcinoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Jan 2022
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications Adenocarcinoma; Carcinoma; Gastric cancer; Oesophageal cancer; Squamous cell cancer
- Focus Proof of concept; Therapeutic Use
- Acronyms iMYC
- 17 Sep 2019 Planned End Date changed from 1 Jul 2019 to 30 Dec 2021.
- 17 Sep 2019 Planned primary completion date changed from 1 Jul 2019 to 30 Dec 2021.
- 24 Mar 2017 According to trial design presented at the 2017 Gastrointestinal Cancers Symposium, 19 patients completed MYC analysis and one patient started treatment.